Detection of the anti-p53 antibody response in malignant and benign pancreatic disease.

doi:10.1038/bjc.1994.443

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Detection of the anti-p53 antibody response in malignant and benign pancreatic disease.

British journal of cancer - 1 Nov 1994

Marxsen J, Schmiegel W, Röder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H

Abstract excerpt

Genomic alterations in the p53 tumour-suppressor gene and overexpression of p53 protein, resulting from gene mutations, are frequently found in pancreatic cancer. In this study we analysed the sera of 160 patients with malignant and benign pancreatic diseases for the presence of circulating antibodies to the p53 protein. The analysis of the sera was performed using two different enzyme-linked immunosorbent assay...

Topics

Adult
Aged
Antibodies
Antibodies, Neoplasm
Antibody Formation
Antibody Specificity
Blotting, Western
Carcinoma, Squamous Cell
Chronic Disease
Codon
Enzyme-Linked Immunosorbent Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Humans

Male

Middle Aged

Mutation

Pancreatic Diseases

Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 7947080
DOI: 10.1038/bjc.1994.443
PMCID: PMC2033558

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-7947080-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of the anti-p53 antibody response in malignant and benign pancreatic disease.PMID 7947080Read ↗

Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.Semantic proximity Read ↗

Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma.Semantic proximity Read ↗

The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status.Semantic proximity Read ↗

Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

[Clinical importance of serum anti-p53 antibodies as tumor markers].Semantic proximity Read ↗

p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.Semantic proximity Read ↗

Analysis of the anti-p53 antibody response in cancer patients.Semantic proximity Read ↗

Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.Semantic proximity Read ↗

Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.Semantic proximity Read ↗

Absence of p53 autoantibodies in sera from glioma patients.Semantic proximity Read ↗

Prevalence and clinical relevance of serum anti-p53 antibodies in patients with cholangiocarcinoma.Semantic proximity Read ↗

p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.